Biricodar dicitrate NEW
| Price | $518 | $1170 | $1920 |
| Package | 1mg | 5mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-06 |
Product Details
| Product Name: Biricodar dicitrate | CAS No.: 174254-13-8 |
| Purity: 97.78% | Supply Ability: 10g |
| Release date: 2026/05/06 |
Product Introduction
Bioactivity
| Name | Biricodar dicitrate |
| Description | Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer. |
| In vitro | Biricodar exhibits activity against both P-glycoprotein (Pgp) and MRP-1, enhancing drug uptake and retention while reversing drug resistance mediated by wild-type BCRP (BCRPR482). In Pgp-expressing 8226/Dox6 cells, biricodar increases the uptake of mitoxantrone and daunorubicin by 55% and 100%, respectively. It enhances their retention by 100% and 60%, respectively, and boosts their cytotoxicity by 3.1- and 6.9-fold, respectively. Furthermore, biricodar has similar effects on HL60/Adr cells (MRP-1) and 8226/MR20 cells (BCRP(R482)), but it has little impact on MCF7 AdVP3000 cells (BCRP(R482T))[1]. VX-710, a non-macrocyclic pipecolinate derivative binding to the FK506 receptor protein, has been shown to restore sensitivity in various multidrug-resistant cells, including myeloma, melanoma, carcinoma, and leukemia[2]. Additionally, biricodar effectively inhibits the photoaffinity labeling of P-glycoprotein by [3H]azidopine or [125I]iodoaryl azido-prazosin, with EC50 values of 0.75 and 0.55 μM[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | α4β2 nAChR | VX-710 | VX710 | NF-κB | NFκB | NF-kB | NFkB | Biricodar Dicitrate | Biricodar |
| Inhibitors Related | Sodium propionate | Kojic acid | Urethane | Uridine | Fumaric acid | 1,4-Naphthoquinone | Adenine | Glucosamine | Ethyl linoleate | D-Psicose | N,N-Dimethylacetamide | N,N-Dicyclohexylcarbodiimide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3100.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $10.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-12 | |
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-13 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY